Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS trial

J. Simon; P. O'Connor; P. Fleming; T. Gray; L. Jacobs; C. Miller; F. Munschauer; R. P. Kinkel; D. Bolibrush; J. Cohen; M. Freedman; U. Webb; H. Rabinowicz; L. Metz; A. Davis; D. Patry; S. Hashimoto; W. Morrison; J. Oger; H. Panitch; K. Costello; C. Bever; W. Stuart; D. Court; D. Stuart; C. Tornatore; D. Barlett; J. Richert; P. Duquette; R. Dubois; G. Bernier; T. Scott; L. Pappert; J. Brillman; W. Fenton; T. Anderson; J. Astruc; J. Rose; J. Kline; J. Burns; T. Murray; P. Weldon; F. Bhan; M. Wall; L. Vining; T. Grabowski; B. Apatoff; K. Arapello; J. Friedman; S. Galetta; D. Pfohl; G. Liu; G. Rice; T. Bental; P. Mandalfind; E. Eggenberger; D. Snider; D. Kaufman; J. Guarnaccia; R. Lesser; J. Goldstein; M. Reiss; E. Carter; G. Glista; L. Rolak; L. Scheller; D. Jacobson; A. Goodman; M. Petrie; D. Mattson; K. Karlin; A. Wallin; D. Stefoski; S. Brod; E. Cerretta; J. Wolinsky; D. Arnold; R. Arnoutelis; L. Durcan; M. Kupersmith; L. Cappolino; J. Herbert; J. Rosenberg; D. McHugh; A. Blumenfeld; C. Smith; D. Kuder; S. Hamilton; S. Thurston; J. McGee; J. O'Bannon; M. Kaufman; M. Butler; S. Putnam; K. Rammohan; A. Stiffort; J. Lynn; J. Selhourst; E. Holzemer

doi:10.1191/1352458502ms819oa

Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS trial

J. Simon, P. O'Connor, P. Fleming, T. Gray, L. Jacobs, C. Miller, F. Munschauer, R. P. Kinkel, D. Bolibrush, J. Cohen, M. Freedman, U. Webb, H. Rabinowicz, L. Metz, A. Davis, D. Patry, S. Hashimoto, W. Morrison, J. Oger, H. PanitchK. Costello, C. Bever, W. Stuart, D. Court, D. Stuart, C. Tornatore, D. Barlett, J. Richert, P. Duquette, R. Dubois, G. Bernier, T. Scott, L. Pappert, J. Brillman, W. Fenton, T. Anderson, J. Astruc, J. Rose, J. Kline, J. Burns, T. Murray, P. Weldon, F. Bhan, M. Wall, L. Vining, T. Grabowski, B. Apatoff, K. Arapello, J. Friedman, S. Galetta, D. Pfohl, G. Liu, G. Rice, T. Bental, P. Mandalfind, E. Eggenberger, D. Snider, D. Kaufman, J. Guarnaccia, R. Lesser, J. Goldstein, M. Reiss, E. Carter, G. Glista, L. Rolak, L. Scheller, D. Jacobson, A. Goodman, M. Petrie, D. Mattson, K. Karlin, A. Wallin, D. Stefoski, S. Brod, E. Cerretta, J. Wolinsky, D. Arnold, R. Arnoutelis, L. Durcan, M. Kupersmith, L. Cappolino, J. Herbert, J. Rosenberg, D. McHugh, A. Blumenfeld, C. Smith, D. Kuder, S. Hamilton, S. Thurston, J. McGee, J. O'Bannon, M. Kaufman, M. Butler, S. Putnam, K. Rammohan, A. Stiffort, J. Lynn, J. Selhourst, E. Holzemer

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

The baseline MRI studies from the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) trial, a randomized, longitudinal, double-blind trial of 383 patients with a first acute clinical demyelinating event and evidence of prior subclinical demyelination on magnetic resonance imaging (MRI) of the brain, provides a large MRI database for patients likely in the earliest stages of multiple sclerosis (MS). High-resolution baseline MRIs revealed a median of 13 T2 lesions (maximum=103 lesions) and 2.05 cm³ of T2 lesion volume (maximum 35.04 cm³), with 30% of patients having one or more enhancing lesions despite receiving a standardized high-dose course of intravenous corticosteroids. Periventricular, discrete, and juxtacortical T2 lesions were present in 99%, 92% and 67% of the patients, respectively. Large (> 6 mm), T1-hypointense, infratentorial, and corpus callosum lesions were present in 69%, 50%, 55%, and 58%, respectively. Clinical presentation groups showed differences in T2 lesion volume, and enhancing lesion number and volume. At baseline, 97%, 81% and 72% of the patients met 'Paty', 'Fazekas', and 'Barkhof' research criteria for MS, respectively, with the percentages similar according to clinical presentation group. These results support and extend those of smaller and/or retrospective series, which have shown substantial subclinical injury, based on brain MRI, at the earliest identifiable stages of disease.

Original language	English
Pages (from-to)	330-338
Number of pages	9
Journal	Multiple Sclerosis
Volume	8
Issue number	4
DOIs	https://doi.org/10.1191/1352458502ms819oa
Publication status	Published - 2002
Externally published	Yes

ASJC Scopus Subject Areas

Neurology
Clinical Neurology

PubMed: MeSH publication types

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Access to Document

10.1191/1352458502ms819oa

Cite this

Simon, J., O'Connor, P., Fleming, P., Gray, T., Jacobs, L., Miller, C., Munschauer, F., Kinkel, R. P., Bolibrush, D., Cohen, J., Freedman, M., Webb, U., Rabinowicz, H., Metz, L., Davis, A., Patry, D., Hashimoto, S., Morrison, W., Oger, J., ... Holzemer, E. (2002). Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS trial. Multiple Sclerosis, 8(4), 330-338. https://doi.org/10.1191/1352458502ms819oa

Simon, J, O'Connor, P, Fleming, P, Gray, T, Jacobs, L, Miller, C, Munschauer, F, Kinkel, RP, Bolibrush, D, Cohen, J, Freedman, M, Webb, U, Rabinowicz, H, Metz, L, Davis, A, Patry, D, Hashimoto, S, Morrison, W, Oger, J, Panitch, H, Costello, K, Bever, C, Stuart, W, Court, D, Stuart, D, Tornatore, C, Barlett, D, Richert, J, Duquette, P, Dubois, R, Bernier, G, Scott, T, Pappert, L, Brillman, J, Fenton, W, Anderson, T, Astruc, J, Rose, J, Kline, J, Burns, J, Murray, T, Weldon, P, Bhan, F, Wall, M, Vining, L, Grabowski, T, Apatoff, B, Arapello, K, Friedman, J, Galetta, S, Pfohl, D, Liu, G, Rice, G, Bental, T, Mandalfind, P, Eggenberger, E, Snider, D, Kaufman, D, Guarnaccia, J, Lesser, R, Goldstein, J, Reiss, M, Carter, E, Glista, G, Rolak, L, Scheller, L, Jacobson, D, Goodman, A, Petrie, M, Mattson, D, Karlin, K, Wallin, A, Stefoski, D, Brod, S, Cerretta, E, Wolinsky, J, Arnold, D, Arnoutelis, R, Durcan, L, Kupersmith, M, Cappolino, L, Herbert, J, Rosenberg, J, McHugh, D, Blumenfeld, A, Smith, C, Kuder, D, Hamilton, S, Thurston, S, McGee, J, O'Bannon, J, Kaufman, M, Butler, M, Putnam, S, Rammohan, K, Stiffort, A, Lynn, J, Selhourst, J & Holzemer, E 2002, 'Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS trial', Multiple Sclerosis, vol. 8, no. 4, pp. 330-338. https://doi.org/10.1191/1352458502ms819oa

@article{74a18b719f764f2ba52825388ee4f236,

title = "Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS trial",

abstract = "The baseline MRI studies from the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) trial, a randomized, longitudinal, double-blind trial of 383 patients with a first acute clinical demyelinating event and evidence of prior subclinical demyelination on magnetic resonance imaging (MRI) of the brain, provides a large MRI database for patients likely in the earliest stages of multiple sclerosis (MS). High-resolution baseline MRIs revealed a median of 13 T2 lesions (maximum=103 lesions) and 2.05 cm3 of T2 lesion volume (maximum 35.04 cm3), with 30% of patients having one or more enhancing lesions despite receiving a standardized high-dose course of intravenous corticosteroids. Periventricular, discrete, and juxtacortical T2 lesions were present in 99%, 92% and 67% of the patients, respectively. Large (> 6 mm), T1-hypointense, infratentorial, and corpus callosum lesions were present in 69%, 50%, 55%, and 58%, respectively. Clinical presentation groups showed differences in T2 lesion volume, and enhancing lesion number and volume. At baseline, 97%, 81% and 72% of the patients met 'Paty', 'Fazekas', and 'Barkhof' research criteria for MS, respectively, with the percentages similar according to clinical presentation group. These results support and extend those of smaller and/or retrospective series, which have shown substantial subclinical injury, based on brain MRI, at the earliest identifiable stages of disease.",

author = "J. Simon and P. O'Connor and P. Fleming and T. Gray and L. Jacobs and C. Miller and F. Munschauer and Kinkel, {R. P.} and D. Bolibrush and J. Cohen and M. Freedman and U. Webb and H. Rabinowicz and L. Metz and A. Davis and D. Patry and S. Hashimoto and W. Morrison and J. Oger and H. Panitch and K. Costello and C. Bever and W. Stuart and D. Court and D. Stuart and C. Tornatore and D. Barlett and J. Richert and P. Duquette and R. Dubois and G. Bernier and T. Scott and L. Pappert and J. Brillman and W. Fenton and T. Anderson and J. Astruc and J. Rose and J. Kline and J. Burns and T. Murray and P. Weldon and F. Bhan and M. Wall and L. Vining and T. Grabowski and B. Apatoff and K. Arapello and J. Friedman and S. Galetta and D. Pfohl and G. Liu and G. Rice and T. Bental and P. Mandalfind and E. Eggenberger and D. Snider and D. Kaufman and J. Guarnaccia and R. Lesser and J. Goldstein and M. Reiss and E. Carter and G. Glista and L. Rolak and L. Scheller and D. Jacobson and A. Goodman and M. Petrie and D. Mattson and K. Karlin and A. Wallin and D. Stefoski and S. Brod and E. Cerretta and J. Wolinsky and D. Arnold and R. Arnoutelis and L. Durcan and M. Kupersmith and L. Cappolino and J. Herbert and J. Rosenberg and D. McHugh and A. Blumenfeld and C. Smith and D. Kuder and S. Hamilton and S. Thurston and J. McGee and J. O'Bannon and M. Kaufman and M. Butler and S. Putnam and K. Rammohan and A. Stiffort and J. Lynn and J. Selhourst and E. Holzemer",

year = "2002",

doi = "10.1191/1352458502ms819oa",

language = "English",

volume = "8",

pages = "330--338",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "4",

}

TY - JOUR

T1 - Baseline MRI characteristics of patients at high risk for multiple sclerosis

T2 - Results from the CHAMPS trial

AU - Simon, J.

AU - O'Connor, P.

AU - Fleming, P.

AU - Gray, T.

AU - Jacobs, L.

AU - Miller, C.

AU - Munschauer, F.

AU - Kinkel, R. P.

AU - Bolibrush, D.

AU - Cohen, J.

AU - Freedman, M.

AU - Webb, U.

AU - Rabinowicz, H.

AU - Metz, L.

AU - Davis, A.

AU - Patry, D.

AU - Hashimoto, S.

AU - Morrison, W.

AU - Oger, J.

AU - Panitch, H.

AU - Costello, K.

AU - Bever, C.

AU - Stuart, W.

AU - Court, D.

AU - Stuart, D.

AU - Tornatore, C.

AU - Barlett, D.

AU - Richert, J.

AU - Duquette, P.

AU - Dubois, R.

AU - Bernier, G.

AU - Scott, T.

AU - Pappert, L.

AU - Brillman, J.

AU - Fenton, W.

AU - Anderson, T.

AU - Astruc, J.

AU - Rose, J.

AU - Kline, J.

AU - Burns, J.

AU - Murray, T.

AU - Weldon, P.

AU - Bhan, F.

AU - Wall, M.

AU - Vining, L.

AU - Grabowski, T.

AU - Apatoff, B.

AU - Arapello, K.

AU - Friedman, J.

AU - Galetta, S.

AU - Pfohl, D.

AU - Liu, G.

AU - Rice, G.

AU - Bental, T.

AU - Mandalfind, P.

AU - Eggenberger, E.

AU - Snider, D.

AU - Kaufman, D.

AU - Guarnaccia, J.

AU - Lesser, R.

AU - Goldstein, J.

AU - Reiss, M.

AU - Carter, E.

AU - Glista, G.

AU - Rolak, L.

AU - Scheller, L.

AU - Jacobson, D.

AU - Goodman, A.

AU - Petrie, M.

AU - Mattson, D.

AU - Karlin, K.

AU - Wallin, A.

AU - Stefoski, D.

AU - Brod, S.

AU - Cerretta, E.

AU - Wolinsky, J.

AU - Arnold, D.

AU - Arnoutelis, R.

AU - Durcan, L.

AU - Kupersmith, M.

AU - Cappolino, L.

AU - Herbert, J.

AU - Rosenberg, J.

AU - McHugh, D.

AU - Blumenfeld, A.

AU - Smith, C.

AU - Kuder, D.

AU - Hamilton, S.

AU - Thurston, S.

AU - McGee, J.

AU - O'Bannon, J.

AU - Kaufman, M.

AU - Butler, M.

AU - Putnam, S.

AU - Rammohan, K.

AU - Stiffort, A.

AU - Lynn, J.

AU - Selhourst, J.

AU - Holzemer, E.

PY - 2002

Y1 - 2002

N2 - The baseline MRI studies from the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) trial, a randomized, longitudinal, double-blind trial of 383 patients with a first acute clinical demyelinating event and evidence of prior subclinical demyelination on magnetic resonance imaging (MRI) of the brain, provides a large MRI database for patients likely in the earliest stages of multiple sclerosis (MS). High-resolution baseline MRIs revealed a median of 13 T2 lesions (maximum=103 lesions) and 2.05 cm3 of T2 lesion volume (maximum 35.04 cm3), with 30% of patients having one or more enhancing lesions despite receiving a standardized high-dose course of intravenous corticosteroids. Periventricular, discrete, and juxtacortical T2 lesions were present in 99%, 92% and 67% of the patients, respectively. Large (> 6 mm), T1-hypointense, infratentorial, and corpus callosum lesions were present in 69%, 50%, 55%, and 58%, respectively. Clinical presentation groups showed differences in T2 lesion volume, and enhancing lesion number and volume. At baseline, 97%, 81% and 72% of the patients met 'Paty', 'Fazekas', and 'Barkhof' research criteria for MS, respectively, with the percentages similar according to clinical presentation group. These results support and extend those of smaller and/or retrospective series, which have shown substantial subclinical injury, based on brain MRI, at the earliest identifiable stages of disease.

AB - The baseline MRI studies from the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) trial, a randomized, longitudinal, double-blind trial of 383 patients with a first acute clinical demyelinating event and evidence of prior subclinical demyelination on magnetic resonance imaging (MRI) of the brain, provides a large MRI database for patients likely in the earliest stages of multiple sclerosis (MS). High-resolution baseline MRIs revealed a median of 13 T2 lesions (maximum=103 lesions) and 2.05 cm3 of T2 lesion volume (maximum 35.04 cm3), with 30% of patients having one or more enhancing lesions despite receiving a standardized high-dose course of intravenous corticosteroids. Periventricular, discrete, and juxtacortical T2 lesions were present in 99%, 92% and 67% of the patients, respectively. Large (> 6 mm), T1-hypointense, infratentorial, and corpus callosum lesions were present in 69%, 50%, 55%, and 58%, respectively. Clinical presentation groups showed differences in T2 lesion volume, and enhancing lesion number and volume. At baseline, 97%, 81% and 72% of the patients met 'Paty', 'Fazekas', and 'Barkhof' research criteria for MS, respectively, with the percentages similar according to clinical presentation group. These results support and extend those of smaller and/or retrospective series, which have shown substantial subclinical injury, based on brain MRI, at the earliest identifiable stages of disease.

UR - http://www.scopus.com/inward/record.url?scp=0036690335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036690335&partnerID=8YFLogxK

U2 - 10.1191/1352458502ms819oa

DO - 10.1191/1352458502ms819oa

M3 - Article

C2 - 12166504

AN - SCOPUS:0036690335

SN - 1352-4585

VL - 8

SP - 330

EP - 338

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 4

ER -

Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS trial

Abstract

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this